Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Eliem, were $92.0 million.